Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EASDAQ: Fighting for a Lost Cause?

This article was originally published in Start Up

Executive Summary

Five years after its formation, Easdaq still hasn't given up the fight to become the pan-European market for growth stocks--but it hasn't won the war either. Despite its aim of providing growth companies with European-wide exposure, using a single regulatory environment and trading system--the Brussels-based exchange has so far failed to become the Nasdaq of Europe.

You may also be interested in...



Is London's AIM the New Nasdaq? Not Yet.

Some observers see London's ten-year old junior market for high-growth, small-to-mid-cap companies as, if not a Nasdaq-in-waiting, then certainly the most likely exchange to rival it. But although AIM is attracting growing numbers of overseas companies, some sheltering from Sarbanes-Oxley, liquidity and follow-on financing issues remain. AIM isn't Europe's Nasdaq, not yet.

Is London's AIM the New Nasdaq? Not Yet.

Some observers see London's ten-year old junior market for high-growth, small-to-mid-cap companies as, if not a Nasdaq-in-waiting, then certainly the most likely exchange to rival it. But although AIM is attracting growing numbers of overseas companies, some sheltering from Sarbanes-Oxley, liquidity and follow-on financing issues remain. AIM isn't Europe's Nasdaq, not yet.

UK Biotech Learns the Hard Way

A bunch of UK biotech firms are in trouble, some forced to restructure and others to seek financing on miserably expensive terms. All wish they'd raised more money during the funding bonanza of 2000. Challenging times such as these reveal lingering cracks--and lack of experience--in strategy and business management. This suggests that UK industry, although it has matured significantly since the brutal blow to confidence dealt by a major product failure at British Biotech during the sector's tender early years, still has some way to go.

Topics

Related Companies

UsernamePublicRestriction

Register

PL007508

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel